NCCN 2021 Virtual Annual Conference
Selected Poster Presentations From the NCCN 2021 Annual Conference
Although once again, the National Comprehensive Cancer Network® (NCCN®) 2021 Annual Conference could not take place on site in Orlando, researchers presented their work virtually in the form of almost...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than...
Melinda L. Telli, MD, on HER2-Positive Breast Cancer: NCCN Guidelines Update
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treat...
Jennifer R. Brown, MD, PhD, on Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors an...
April K. Salama, MD, on Managing Melanoma Brain Metastases
April K. Salama, MD, of Duke Cancer Institute, discusses the shift in recent years, as more effective therapies have become available, toward integrating systemic upfront treatment of patients with br...
David G. Pfister, MD, on Supportive Care in Head and Neck Cancers: Multidisciplinary Management
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nutritional issues; side effe...
Thomas K. Varghese, Jr, MD, on the Effects of the COVID-19 Pandemic on Cancer Care
Thomas K. Varghese, Jr, MD, of Huntsman Cancer Institute at the University of Utah, summarizes a panel discussion on how the COVID-19 pandemic has interrupted cancer screenings, when telemedicine work...
Mary F. Mulcahy, MD, and Crystal S. Denlinger, MD, on NCCN Guidelines Updates: Gastric and Esophageal Cancers
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatme...
Eric Jonasch, MD, on Hereditary Renal Cell Carcinoma: Screening, Diagnosis, and Management
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the several hereditary renal cell cancer syndromes, the importance of surveillance for both renal and nonrenal manifes...
Alexander E. Perl, MD, on Acute Myeloid Leukemia: Treatment Updates
Alexander E. Perl, MD, of the Abramson Cancer Center at the University of Pennsylvania, discusses the major changes in 2021 to the NCCN Clinical Practice Guidelines in Oncology for managing acute myel...
Lori J. Wirth, MD, on Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion po...
Shaji K. Kumar, MD, on Multiple Myeloma: NCCN Guidelines Update
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the latest data on treating patients with multiple myeloma, including standard-of-care induction before stem cell transplant; the role ...
Gabrielle A. Zecha, PA-C, MHA, and Aaron Begue, MS, RN, NP-C, OCN: The Role of Advanced Practice Providers in Oncology Care
Gabrielle A. Zecha, PA-C, MHA, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, and Aaron Begue, MS, RN, NP-C, OCN, of Memorial Sloan Kettering Cancer Center, discuss how a...
Susan M. Swetter, MD, on Molecular Testing for Cutaneous Melanoma
Susan M. Swetter, MD, of Stanford Cancer Institute, discusses molecular prognostic tests for cutaneous melanoma, which may improve staging accuracy, reduce unnecessary sentinel lymph node biopsies, an...
Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the changing therapeutic landscape in which atezolizumab, avelumab, and pembrolizumab have either been app...
Robert Winn, MD, on Strategies for Reducing Racial Disparities in Oncology
Robert Winn, MD, of the Virginia Commonwealth University Massey Cancer Center, discusses the creation of a health equity report card to track how institutions are dealing with disparities in oncology ...
William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating pa...
Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers
Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vaccination rates, thus loweri...
Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer
Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging ...
